Dogs with cognitive dysfunction syndrome: A natural model of Alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 3, 2012, Pages 298-314

  Bosch, Maria Neus ^a   Pugliese, Marco ^a   Gimeno Bayón, Javier ^a   Rodríguez, Manuel José ^a   Mahy, Nicole ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aging; Amyloid beta; Animal model; Canine cognitive dysfunction syndrome; Family dog; Therapies

Indexed keywords

ADRANAFIL; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; ANIPRIL; CENTRAL STIMULANT AGENT; FREE RADICAL; GERIACTIVE; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; NICERGOLINE; NOVIFIT; NUTRACEUTICAL; OLIGOMER; PHOSPHATIDYLSERINE; PLANT EXTRACT; PROPENTOFYLLINE; PYRIDOXINE; S ADENOSYLMETHIONINE TOSYLATE SULFATE; SELEGILINE; SENILIFE; THIOCTIC ACID; UNCLASSIFIED DRUG; VACCINE; VITAMIN; VITAMIN B GROUP;

AGING; ALZHEIMER DISEASE; BEHAVIOR CHANGE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DIET; ENVIRONMENTAL ENRICHMENT; EXERCISE; EXPERIMENTAL MODEL; GLIA; HUMAN; IMMUNOTHERAPY; LEARNING DISORDER; MEMORY DISORDER; MICROGLIA; MULTIINFARCT DEMENTIA; NERVE CELL; NEUROPATHOLOGY; NEUROPATHY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; VITAMIN SUPPLEMENTATION;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MEMORY DISORDERS; SPECIES SPECIFICITY;

EID: 84860295330     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800107546     Document Type: Review

References (152)

1. Woodruff-Pak DS. Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 15(4): 507-521 (2008).
2. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res 10(4): 299-305 (1991).
3. Tekirian TL, Cole GM, Russell MJ, Yang F, Wekstein DR, Patel E, et al. Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. Neurobiol Aging 17(2): 249-257 (1996).
4. Price DL, Martin LJ, Sisodia SS, Wagster MV, Koo EH, Walker LC, et al. Aged non-human primates: an animal model of ageassociated neurodegenerative disease. Brain Pathol 1(4): 287-296 (1991).
5. Head E, Moffat K, Das P, Sarsoza F, Poon WW, Landsberg G, et al. [beta]-Amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 26(5): 749-763 (2005).
6. Sarasa M, Pesini P. Natural Non-Trasgenic Animal Models for Research in Alzheimer's Disease. Curr Alzheimer Res. Apr;6(2):171-178 (2009).
7. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW. The canine as an animal model of human aging and dementia. Neurobiol Aging 17(2): 259-268 (1995).
8. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99-102 (1996).
9. Gotz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9(7): 532-544 (2008).
10. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Experimental Neurology 223(2): 422-431 (2010).
11. Cotman CW, Head E. The Canine (Dog) Model of Human Aging and Disease: Dietary, Environmental and Immunotherapy Approaches. Journal of Alzheimer's Disease. Jan 1;15(4):685-707 (2008).
12. Adams B, Chan A, Callahan H, Milgram NW. The canine as a model of human cognitive aging: recent developments. Prog. Neuropsychopharmacol. Biol Psychiatry 24(5): 675-692 (2000).
13. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, et al. Iron-Export Ferroxidase Activity of beta-Amyloid Precursor Proteini is inhibited by Zinc in Alzheimer's Disease. Cell Sep 14; In Press (2010)
14. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB, et al. The Dog Genome: Survey Sequencing and Comparative Analysis. Science 301(5641): 1898-1903 (2003).
15. Sarasa L, Gallego C, Monleón I, Olvera A, Canudas J, Montañás M, et al. Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing. Neuroscience 171(4): 1091-1101 (2010).
16. Pugliese M, Mascort J, Mahy N, Ferrer I. Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neuropathologica112(2): 175-183 (2006).
17. Head E, Moffat K, Das P, Sarsoza F, Poon WW, Landsberg G, et al. Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 26(5): 749-763 (2005).
18. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054):184-185 (1992).
19. Kiatipattanasakul W, Nakamura Sichiro, Hossain MM, Nakayama H, Uchino T, Shumiya S, et al. Apoptosis in the aged dog brain. Acta Neuropathologica 92(3): 242-248 (1996).
20. Bernedo V, Insua D, Suárez M-L, Santamarina G, Sarasa M, Pesini P. Beta-amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog. J Comp Neurol 513(4): 417-429 (2009).
21. Dimakopoulos AC, Mayer RJ. Aspects of neurodegeneration in the canine brain. J Nutr 132(6 Suppl 2): 1579S-82S (2002).
22. Head E, Pop V, Sarsoza F, Kayed R, Beckett TL, Studzinski CM, et al. Amyloid-β Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines. J Alzheimers Dis 20(2): 637-646 (2010).
23. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, et al. Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice. J Biol Chem 281(7): 4292-4299 (2006).
24. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19(R1): R12-20 (2010).
25. Head E, Thornton PL, Tong L, Cotman CW. Initiation and propagation of molecular cascades in human brain aging: Insight from the canine model to promote successful aging. Prog Neuropsychopharmacol Biol Psychiatry 24(5): 777-786 (2000).
26. Alkadhi KA, Alzoubi KH, Srivareerat M, Tran TT. Chronic Psychosocial Stress Exacerbates Impairment of Synaptic Plasticity in β-Amyloid Rat Model of Alzheimer's Disease: Prevention by Nicotine. Curr Alzheimer Res [Internet] 2011 Apr 1 [cited 2011 Apr 18]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21453245
27. Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 88(4): 475-486 (2010).
28. Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8): 916-919 (2000).
29. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15(4): 505-514 (2003).
30. DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15): 8850-8855 (2001).
31. Landsberg G. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Prog Neuropsychopharmacol. Biol Psychiatry 29(3): 471-479 (2005).
32. Pugliese M, Carrasco JL, Andrade C, Mas E, Mascort J, Mahy N. Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia. Prog Neuropsychopharmacol Biol Psychiatry 29(4): 603-610 (2005).
33. Shepherd AJ. Results of the 2007 AVMA survey of US pet-owning households regarding use of veterinary services and expenditures. J Am Vet Med Assoc 233(5): 727-728 (2008).
34. Mosier JE. Effect of aging on body systems of the dog. Vet Clin North Am Small Anim Pract 19(1): 1-12 (1989).
35. Ruehl WW, Bruyette DS, DePaoli A, Cotman CW, Head E, Milgram NW, et al. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. Prog Brain Res 106: 217-225 (1995).
36. Amerincan Psychiatric Association. Manual of Mental Disorders Wasington (1994)
37. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW. beta-Amyloid Accumulation Correlates with Cognitive Dysfunction in the Aged Canine. Neurobiol Learn Mem 66(1): 11-23 66(1): 11-23 (1996).
38. Neilson JC, Hart BL, Cliff KD, Ruehl WW. Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. J Am Vet Med Assoc 218(11): 1787-1791 (2001).
39. Salvin HE, McGreevy PD, Sachdev PS, Valenzuela MJ. Under diagnosis of canine cognitive dysfunction: A cross-sectional survey of older companion dogs. J Vet 184(3): 277-281 (2010).
40. Borràs D, Ferrer I, Pumarola M. Age-related Changes in the Brain of the Dog. Veterinary Pathology Online 36(3): 202-211 (1999).
41. González-Soriano J, Marín García P, Contreras-Rodríguez J, Martínez-Sainz P, Rodríguez-Veiga E. Age-related changes in the ventricular system of the dog brain. Ann Anat 183(3): 283-291 (2001).
42. Reifinger M. [Volumetric examination of senile brain involution in dogs] Anat Histol Embryol 26(2): 141-146 (1997).
43. Kimotsuki T, Nagaoka T, Yasuda M, Tamahara S, Matsuki N, Ono K. Changes of magnetic resonance imaging on the brain in beagle dogs with aging. J Vet Med Sci 67(10): 961-967 (2005).
44. Tapp PD, Head K, Head E, Milgram NW, Muggenburg BA, Su MY. Application of an automated voxel-based morphometry technique to assess regional gray and white matter brain atrophy in a canine model of aging. Neuroimage 29(1): 234-244 (2006).
45. Pugliese M, Carrasco JL, Gomez-Anson B, Andrade C, Zamora A, Rodríguez MJ, et al. Magnetic resonance imaging of cerebral involutional changes in dogs as markers of aging: An innovative tool adapted from a human visual rating scale. The Veterinary Journal Nov; 186(2): 166-171 (2010).
46. Alom J, Mahy JN, Brandi N, Tolosa E. Cerebrospinal fluid taurine in Alzheimer's disease. Ann Neurol 30(5): 735 (1991).
47. Wahlund L-O, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neuroscience Letters 339(2): 99-102 (2003).
48. Munguia ME, Govezensky T, Martinez R, Manoutcharian K, Gevorkian G. Identification of amyloid-beta 1-42 binding protein fragments by screening of a human brain cDNA library. Neurosci Lett 397(1-2): 79-82 (2006).
49. Papaioannou N, Tooten PC, van Ederen AM, Bohl JR, Rofina J, Tsangaris T, et al. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 8(1):11-21 (2001).
50. Hipkiss AR. Accumulation of altered proteins and ageing: causes and effects. Exp Gerontol 41(5): 464-473 (2006).
51. Oppermann UC, Salim S, Tjernberg LO, Terenius L, Jörnvall H. Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease. FEBS Lett 451(3): 238-242 (1999).
52. Ramonet D, Rodríguez MJ, Fredriksson K, Bernal F, Mahy N. In vivo neuroprotective adaptation of the glutamate/glutamine cycle to neuronal death. Hippocampus 14(5): 586-594 (2004).
53. Schurr A. Lactate, glucose and energy metabolism in the ischemic brain (Review). Int J Mol Med 10(2): 131-136 (2002).
54. Gladden LB. Lactate metabolism: a new paradigm for the third millennium. J Physiol 558(1): 5-30 (2004).
55. Rodríguez MJ, Robledo P, Andrade C, Mahy N. In vivo coordinated interactions between inhibitory systems to control glutamate-mediated hippocampal excitability. J. Neurochem. Nov;95(3):651-661 (2005).
56. Russell MJ, White R, Patel E, Markesbery WR, Watson CR, Geddes JW. Familial influence on plaque formation in the beagle brain. Neuroreport 3(12): 1093-1096 (1992).
57. Rofina JE, Singh K, Skoumalova-Vesela A, van Ederen AM, van Asten AJAM, Wilhelm J, et al. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 11(2): 90-100 (2004).
58. Dimakopoulos AC, Mayer RJ. Aspects of neurodegeneration in the canine brain. J Nutr 32(6 Suppl 2):1579S-82S (2002).
59. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW. Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem 88(2): 249-259 (2007).
60. Márquez M, Pérez L, Serafín A, Teijeira S, Navarro C, Pumarola M. Characterisation of Lafora-like bodies and other polyglucosan bodies in two aged dogs with neurological disease. J Vet 183(2): 222-225 (2010).
61. Ramonet D, de Yebra L, Fredriksson K, Bernal F, Ribalta T, Mahy N. Similar calcification process in acute and chronic human brain pathologies. J Neurosci Res 83(1): 147-156 (2006).
62. Mahy N, Prats A, Riveros A, Andrés N, Bernal F. Basal ganglia calcification induced by excitotoxicity: an experimental model characterised by electron microscopy and X-ray microanalysis. Acta Neuropathol 98(3): 217-225 (1999).
63. Ishihara T, Gondo T, Takahashi M, Uchino F, Ikeda S, Allsop D, et al. Immunohistochemical and immunoelectron microscopical characterization of cerebrovascular and senile plaque amyloid in aged dogs' brains. Brain Res 548(1-2): 196-205 (1991).
64. Miyawaki K, Nakayama H, Matsuno S, Tamaoka A, Doi K. Threedimensional and fractal analyses of assemblies of amyloid beta protein subtypes [Abeta40 and Abeta42(43)] in canine senile plaques. Acta Neuropathol 103(3): 228-236 (2002).
65. Nakamura S, Tamaoka A, Sawamura N, Kiatipattanasakul W, Nakayama H, Shoji S, et al. Deposition of amyloid beta protein (A beta) subtypes [A beta 40 and A beta 42(43)] in canine senile plaques and cerebral amyloid angiopathy. Acta Neuropathol 94(4): 323-328 (1997).
66. Shimada A, Kuwamura M, Umemura T, Takada K, Ohama E, Itakura C. Modified Bielschowsky and immunohistochemical studies on senile plaques in aged dogs. Neurosci Lett 129(1): 25-28 (1991).
67. Hou Y, White RG, Bobik M, Marks JS, Russell MJ. Distribution of beta-amyloid in the canine brain. Neuroreport 8(4): 1009-1012 (1997).
68. Pugliese M, Geloso MC, Carrasco JL, Mascort J, Michetti F, Mahy N. Canine cognitive deficit correlates with diffuse plaque maturation and S100β (-) astrocytosis but not with insulin cerebrospinal fluid level. Acta Neuropathol 111(6): 519-528 (2006).
69. Araujo JA, Studzinski CM, Milgram NW. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog. Neuropsychopharmacol. Biol Psychiatry 29(3): 411-422 (2005).
70. Pugliese M, Gangitano C, Ceccariglia S, Carrasco JL, Del Fà A, Rodríguez MJ, et al. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes. Brain Res 1139: 85-94 (2007).
71. Shimada A, Kuwamura M, Awakura T, Umemura T, Itakura C. An immunohistochemical and ultrastructural study on age-related astrocytic gliosis in the central nervous system of dogs. J Vet Med Sci 54(1): 29-36 (1992).
72. Rofina J, van Andel I, van Ederen AM, Papaioannou N, Yamaguchi H, Gruys E. Canine counterpart of senile dementia of the Alzheimer type: amyloid plaques near capillaries but lack of spatial relationship with activated microglia and macrophages. Amyloid un 10(2): 86-96 (2003).
73. Pugliese M, Carrasco JL, Geloso MC, Mascort J, Michetti F, Mahy N. Aminobutyric acidergic interneuron vulnerability to aging in canine prefrontal cortex. J Neurosci Res 77(6): 913-920 (2004).
74. Hof PR, Bogaert YE, Rosenthal RE, Fiskum G. Distribution of neuronal populations containing neurofilament protein and calcium-binding proteins in the canine neocortex: regional analysis and cell typology. J Chem Neuroanat 11(2): 81-98 (1996).
75. Fonseca M, Soriano E. Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer's disease. Brain Res 691(1-2): 83-91 (1995).
76. Sampson VL, Morrison JH, Vickers JC. The Cellular Basis for the Relative Resistance of Parvalbumin and Calretinin Immunoreactive Neocortical Neurons to the Pathology of Alzheimer's Disease. Exp Neurol 145(1): 295-302 (1997).
77. Andressen C, Blümcke I, Celio MR. Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res 271(2): 181-208 (1993).
78. Alberdi E, Sánchez-Gómez MV, Cavaliere F, Pérez-Samartín A, Zugaza JL, Trullas R, et al. Amyloid [beta] oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47(3): 264-272 (2010).
79. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35(3): 352-358 (2009).
80. Skoumalova A, Rofina J, Schwippelova Z, Gruys E, Wilhelm J. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol 38(6): 711-719 (2003).
81. Wegiel J, Wisniewski HM, Sołtysiak Z. Region-and cell-typespecific pattern of tau phosphorylation in dog brain. Brain Res 802(1-2): 259-266 (1998).
82. Bi X, Head E, Cotman CW, Lynch G. Spatial patterns of mammalian brain aging: distribution of cathepsin D-immunoreactive cell bodies and dystrophic dendrites in aging dogs resembles that in Alzheimer's disease. J Comp Neurol 464(3): 371-381 (2003).
83. Milgram NW, Head E, Weiner E, Thomas E. Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Behav Neurosci 108(1): 57-68 (1994).
84. Callahan H, Ikeda-douglas C, Head E, Cotman CW, Milgram NW. Development of a protocol for studying object recognition memory in the dog. Prog Neuropsychopharmacol Biol Psychiatry 24(5): 693-707 (2000).
85. Head E, Mehta R, Hartley J, Kameka M, Cummings BJ, Cotman CW, et al. Spatial learning and memory as a function of age in the dog. Behav Neurosci 109(5): 851-858 (1995).
86. Milgram NW, Adams B, Callahan H, Head E, Mackay B, Thirlwell C, et al. Landmark discrimination learning in the dog. Learn Mem (1): 54-61 (1999).
87. Adams B, Chan A, Callahan H, Siwak C, Tapp D, Ikeda-Douglas C, et al. Use of a delayed non-matching to position task to model age-dependent cognitive decline in the dog. Behav. Brain Res 108(1): 47-56 (2000).
88. Chan ADF, Nippak PMD, Murphey H, Ikeda-Douglas CJ, Muggenburg B, Head E, et al. Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility. Behav Neurosci 116(3): 443-454 (2002).
89. Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW. Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging 19(5): 415-425 (1998).
90. Colle M-A, Hauw J-J, Crespeau F, Uchihara T, Akiyama H, Checler F, et al. Vascular and parenchymal Abeta deposition in the aging dog: correlation with behavior. Neurobiol Aging 21(5): 695-704 (2000).
91. Rofina JE, van Ederen AM, Toussaint MJM, Secrve M, van der Spek A, van der Meer I, et al. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Research 1069(1): 216-226 (2006).
92. Satou T, Cummings BJ, Head E, Nielson KA, Hahn FF, Milgram NW, et al. The progression of [beta]-amyloid deposition in the frontal cortex of the aged canine. Brain Res 774(1-2): 35-43 (1997).
93. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 5(9): e12244 (2010).
94. Alafuzoff I, Helisalmi S, Heinonen EH, Reinikainen K, Hallikainen M, Soininen H, et al. Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eur J Clin Pharmacol 55(11-12): 815-819 (2000).
95. Wilcock GK, Birks J, Whitehead A, Evans SJG. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry 17(2): 175-183 (2002).
96. Milgram NW, Ivy GO, Head E, Murphy MP, Wu PH, Ruehl WW, et al. The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog. Neurochem Res 18(12): 1211-1219 (1993).
97. Siwak CT, Callahan H, Milgram NW. Adrafinil: effects on behavior and cognition in aged canines. Prog. Neuropsychopharmacol. Biol Psychiatry 24(5): 709-726 (2000).
98. Campbell S, Trettien A, Kozan B. A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. Vet Ther 2(1): 24-39 (2001).
99. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82(2): 57-66 (1998).
100. Paterson IA, Juorio AV, Boulton AA. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 55(6): 1827-1837 (1990).
101. Studzinski CM, Araujo JA, Milgram NW. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog. Neuropsychopharmacol. Biol Psychiatry 29(3): 489-498 (2005).
102. Peremans K, Audenaert K, Blanckaert P, Jacobs F, Coopman F, Verschooten F, et al. Effects of aging on brain perfusion and serotonin-2A receptor binding in the normal canine brain measured with single photon emission tomography. Prog. Neuropsychopharmacol. Biol Psychiatry 26(7-8): 1393-1404 (2002).
103. Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, et al. Therapeutic use of nicergoline. Clin Drug Investig 28(9): 533-552 (2008).
104. Giardino L, Giuliani A, Battaglia A, Carfagna N, Aloe L, Calza' L. Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion). Neuroscience 109(3): 487-497 (2002).
105. Ringheim GE. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ann NY Acad Sci 903: 529-534 (2000).
106. Frampton M, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev (2): CD002853 (2003).
107. Cannarozzi G, Schneider A, Gonnet G. A Phylogenomic Study of Human, Dog, and Mouse. PLoS Comput Biol 3(1): (2007).
108. Blount DG, Pritchard DI, Heaton PR. Age-related alterations to immune parameters in Labrador retriever dogs. Vet Immunol Immunopathol 108(3-4): 399-407 (2005).
109. Greeley EH, Ballam JM, Harrison JM, Kealy RD, Lawler DF, Segre M. The influence of age and gender on the immune system: a longitudinal study in Labrador Retriever dogs. Vet Immunol Immunopathol 82(1-2): 57-71 (2001).
110. Greeley EH, Spitznagel E, Lawler DF, Kealy RD, Segre M. Modulation of canine immunosenescence by life-long caloric restriction. Vet Immunol Immunopathol 111(3-4): 287-299 (2006).
111. Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Martorelli V, et al. The immune system in the elderly: II. Specific cellular immunity. Immunol Res 20(2):109-115 (1999).
112. Strasser A, Teltscher A, May B, Sanders C, Niedermuller H. Ageassociated Changes in the Immune System of German Shepherd Dogs. J Vet Med Series A 47(3): 181-192 (2000).
113. Horiuchi Y, Nakajima Y, Nariai Y, Asanuma H, Kuwabara M, Yukawa M. Th1/Th2 balance in canine peripheral blood lymphocytes--a flow cytometric study. Vet Immunol Immunopathol 118(3-4):179-185 (2007).
114. Sakata-Kaneko S, Wakatsuki Y, Matsunaga Y, Usui T, Kita T. Altered Th1/Th2 commitment in human CD4+ T cells with ageing. Clin Exp Immunol 120(2): 267-273 (2000).
115. Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. Semin Immunopathol 32(1):79-90 (2010).
116. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. Feb;24(2):179-189 (2006).
117. Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5(2): 101-104 (1999).
118. Day MJ. Canine sino-nasal aspergillosis: parallels with human disease. Med Mycol 47(s1): S315-S323 (2009).
119. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, et al. A Two-Year Study with fibrillar beta-Amyloid (A-beta) Immunization in Aged Canines: Effects on Cognitive Function and Brain A{beta}. J Neurosci 28(14): 3555-3566 (2008).
120. DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease. Exp Neurol 149(2): 329-340 (1998).
121. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382(6593): 716-719 (1996).
122. Alarcón R, Fuenzalida C, Santibáñez M, von Bernhardi R. Expression of Scavenger Receptors in Glial Cells. J Biol Chem 280(34): 30406-30415 (2005).
123. Streit WJ, Mrak RE, Griffin WST. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 1: 14-14 (2004).
124. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, et al. Innate immunity and transcription of MGATIII and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA 104(31): 12849-12854 (2007).
125. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. Apr;13(4):432-438 (2007).
126. von Bernhardi R. Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go? J Alzheimers Dis 19(2): 405-421 (2010).
127. Algotsson A, Winblad B. The integrity of the blood?brain barrier in Alzheimer?s disease. Acta Neurol Scand 115(6): 403-408 (2007).
128. Di Filippo M, Sarchielli P, Picconi B, Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immunecentred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 29(8): 402-412 (2008).
129. Bachmeier CJ, Beaulieu-Abdelahad D, Mullan MJ, Paris D. Epitope-dependent effects of beta-amyloid antibodies on beta-amyloid clearance in an in vitro model of the blood-brain barrier. Microcirculation [Internet] 2011 Mar 8 [cited 2011 Apr 1];Available from: http://www.ncbi.nlm.nih.gov/pubmed/21418385
130. Milgram NW. Cognitive experience and its effect on agedependent cognitive decline in beagle dogs. Neurochem Res 28(11):1677-1682 (2003).
131. Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Murphey H, Muggenburg B, et al. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a twoyear longitudinal study. Neurobiol Aging 26(1): 77-90 (2005).
132. Milgram NW, Head E, Muggenburg B, Holowachuk D, Murphey H, Estrada J, et al. Landmark discrimination learning in the dog: effects of age, an antioxidant fortified food, and cognitive strategy. Neuroscience & Biobehavioral Reviews 26(6): 679-695 (2002).
133. Milgram NW, Head E, Zicker SC, Ikeda-Douglas C, Murphey H, Muggenberg BA, et al. Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Exp. Gerontol. May;39(5):753-765 (2004).
134. Head E, Nukala VN, Fenoglio KA, Muggenburg BA, Cotman CW, Sullivan PG. Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. Exp Neurol 220(1): 171-176 (2009).
135. Cotman CW, Head E, Muggenburg BA, Zicker S, Milgram NW. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging 23(5): 809-818 (2002).
136. Head E, Zicker SC. Nutraceuticals, aging, and cognitive dysfunction. Vet Clin North Am Small Anim Pract 34(1): 217-228 (2004).
137. Ikeda-Douglas CJ, Zicker SC, Estrada J, Jewell DE, Milgram NW. Prior experience, antioxidants, and mitochondrial cofactors improve cognitive function in aged beagles. Vet Ther 5(1): 5-16 (2004).
138. Fahnestock M, Marchese M, Head E, Pop V, Michalski B, Milgram WN, et al. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol Aging [Internet] 2010 May 4 [cited 2010 Oct 12];Available from: http://www.ncbi.nlm.nih.gov/pubmed/20447733
139. Rème CA, Dramard V, Kern L, Hofmans J, Halsberghe C, Mombiela DV. Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: a double-blinded, placebocontrolled trial. Vet Ther 9(2): 69-82 (2008).
140. Cotel M-C, Jawhar S, Christensen DZ, Bayer TA, Wirths O. Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice. Neurobiol Aging [Internet] 2010 Mar 30; Available from: http://www.ncbi.nlm.nih.gov/pubmed/20359774
141. Herring A, Ambrée O, Tomm M, Habermann H, Sachser N, Paulus W, et al. Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Exp Neurol 216(1): 184-192 (2009).
142. Nippak PMD, Mendelson J, Muggenburg B, Milgram NW. Enhanced spatial ability in aged dogs following dietary and behavioural enrichment. Neurobiol Learn Mem 87(4): 610-623 (2007).
143. Pop V, Head E, Hill M-A, Gillen D, Berchtold NC, Muggenburg BA, et al. Synergistic Effects of Long-Term Antioxidant Diet and Behavioral Enrichment on β-Amyloid Load and Non-Amyloidogenic Processing in Aged Canines. J Neuroscience 30(29): 9831-9839 (2010).
144. Siwak CT, Tapp PD, Head E, Zicker SC, Murphey HL, Muggenburg BA, et al. Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Prog Neuropsychopharmacol Biol Psychiatry 29(3): 461-469 (2005).
145. Martin LJ, Pardo CA, Cork LC, Price DL. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am J Pathol 145(6):1358-1381 (1994).
146. Iijima K, Iijima-Ando K. Drosophila Models of Alzheimer's Amyloidosis: The Challenge of Dissecting the Complex Mechanisms of Toxicity of Amyloid-β 42. J Alzheimers Dis 15(4):523-540 (2008).
147. Khurana V. Modeling Tauopathy in the fruit fly Drosophila melanogaster. J Alzheimers Dis 15(4): 541-553 (2008).
148. Sparks DL, Scheff SW, Hunsaker JC, Liu H, Landers T, Gross DR. Induction of Alzheimer-like [beta]-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol. Exp Neurol 126(1): 88-94 (1994).
149. Frautschy SA, Yang F, Calderón L, Cole GM. Rodent models of Alzheimer's disease: Rat a[beta] infusion approaches to amyloid deposits. Neurobiol Aging 17(2): 311-321 (1995).
150. Pallas M, Camins A, Smith MA, Perry G, Lee H-gon, Casadesus G. From aging to Alzheimer's disease: unveiling «the switch» with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 15(4): 615-624 (2008).
151. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. Jan;4(1):97-100 (1998).
152. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293(5534): 1487-1491 (2001).